CMMB News and Press, Chemomab Therapeutics Ltd. From 06/21/23

Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 PR Newswire ─ Treatment with CM-101 Improves Additional Biomarkers of Fibrosis and Inflammation, `Reinforcing and Extending Initial S...

2023-06-05 07:31:50 ET Clinical-stage biotechnology company, Chemomab Therapeutics ( NASDAQ: CMMB ) announces that Adi Mor, PhD, co-Founder and former CEO and current Director and Chief Scientific Officer, has been reappointed to the role of CEO, replacing Dale Pfost, P...

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update PR Newswire ─Adi Mor, PhD, Co-founder, Board Director and Chief Scientific Officer, Reappointed to CEO Role ─ ─Sigal Fattal, Vice President Financ...

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis PR Newswire ── New Patient Data Further Implicates CCL24 in Fibrotic Disease Pathology and Prognosis and ...

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences PR Newswire TEL AVIV, Israel , May 24, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and developme...

2023-05-14 11:20:23 ET Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Conference Call May 11, 2023 08:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer ...

2023-05-11 11:44:29 ET Chemomab Therapeutics - ADR press release ( NASDAQ: CMMB ): Q1 GAAP EPS of -$0.04 in-line. Cash Position: Cash, cash equivalents and short-term bank deposits were $32.8 million as of March 31, 2023, compared to $39.9 million at December 31, 2022. ...

Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update PR Newswire ─Reported Top-line Results from CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients Demonstrating Safety and Positive Activity Across Multiple Fibrotic and ...

Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference PR Newswire TEL AVIV, Israel , April 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development o...

Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update PR Newswire This Webcast and Call Replaces and Supplements the Chemomab Corporate Update Originally Scheduled for April 17, 2023 TEL AVIV, Israel , April ...